Panidis D, Vavilis D, Rousso D, Panidou E, Kalogeropoulos A
Third Department of Obstetrics and Gynecology, Aristotelian University of Thessaloniki, Hippokration Hospital, Greece.
Gynecol Endocrinol. 1992 Mar;6(1):19-24. doi: 10.3109/09513599209081002.
Ten patients suffering from endometriosis were treated with danazol at a dose of 200 mg three times daily for 6 months. To evaluate prolactin secretion, a thyrotropin releasing hormone (TRH) test and an insulin challenge test were carried out in the follicular phase before treatment, during the 6th month of treatment and after the reappearance of the second menses. The same tests were also performed, only once, in the follicular phase of ten normal women. The absence of a significant difference in basal prolactin levels as well as the response to the TRH and insulin challenge tests between controls and patients with endometriosis, before and after danazol treatment, support the view that hyperprolactinemia should not be considered as a cause of infertility in endometriotic women. Furthermore, the significant reduction of prolactin response to provocative tests during danazol treatment may be associated with the low estrogen levels caused by the medication. Finally, the inadequate prolactin response to insulin-induced hypoglycemia in patients with endometriosis and in normal women shows that this provocative test is not so effective for hypothalamic stimulation of prolactin.
十名患有子宫内膜异位症的患者接受了达那唑治疗，剂量为每日三次，每次200毫克，持续6个月。为了评估催乳素分泌情况，在治疗前的卵泡期、治疗的第6个月以及第二次月经复现后，对患者进行了促甲状腺激素释放激素（TRH）试验和胰岛素激发试验。同样的试验也仅在十名正常女性的卵泡期进行了一次。在达那唑治疗前后，对照组和子宫内膜异位症患者的基础催乳素水平以及对TRH和胰岛素激发试验的反应均无显著差异，这支持了高催乳素血症不应被视为子宫内膜异位症女性不孕原因的观点。此外，达那唑治疗期间催乳素对激发试验的反应显著降低可能与该药物导致的低雌激素水平有关。最后，子宫内膜异位症患者和正常女性对胰岛素诱导的低血糖的催乳素反应不足表明，这种激发试验对下丘脑刺激催乳素的效果不太理想。
